Atezolizumab to remain licensed in US for untreated metastatic bladder cancer following updated review

It was previously granted accelerated approval for locally advanced/ metastatic urothelial cancer in high PD-L1 expressive tumours on the basis of preliminary results of a phase II study. The IMvigor130 phase III trial has confirmed a significant progression free survival benefit

Biospace Inc.